Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

NCT03741127 · tracked via the Priya Life Science USA tracker

Sponsor

Poseida Therapeutics, Inc.

Phase

Phase 1

Started

2018-10-29

Last updated

2026-03-04

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

Rimiducid may be administered as indicated

Rimiducid may be administered as indicated: Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.

Study summary

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol. * Subject has provided informed consent. Exclusion Criteria: * None

Primary outcome measure(s)

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — Treatment with P-BCMA-101 through year 15
Incidence and severity of treatment-emergent adverse events to evaluate the long-term safety of P-BCMA-101

Trial sites (13)

Facility	City	Region
University of California Davis	Davis	California
University of California, San Diego	San Diego	California
University of California San Francisco	San Francisco	California
Colorado Blood Cancer Institute	Denver	Colorado
University of Chicago	Chicago	Illinois
University of Kansas Cancer Center	Westwood	Kansas
University of Maryland Greenebaum Comprehensive Cancer Center	Baltimore	Maryland
Johns Hopkins University	Baltimore	Maryland
Wayne State - Karmanos Cancer Institute	Detroit	Michigan
University of Pennsylvania	Philadelphia	Pennsylvania
Sarah Cannon Research Institute at Tennessee Oncology	Nashville	Tennessee
Vanderbilt University Medical Center	Nashville	Tennessee
MD Anderson Cancer Center	Houston	Texas

More Poseida Therapeutics, Inc. trials in the USA

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies Active, not recruiting

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors Active, not recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma Active, not recruiting

Other trials for the same condition

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma Recruiting

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma Active, not recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies Recruiting

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma Active, not recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03741127 on ClinicalTrials.gov ↗ ← All trials in the USA